Mr. Spolders has 30 years of experience in the biotech industry in Europe and the U.S. Throughout his career, Mr. Spolders has been instrumental in forging large pharma-biotech collaborations, growing research and development organizations, defining new product opportunities, and protecting intellectual property. In addition to direct management experience, Mr. Spolders has served on the board of Organon Teknika (Akzo Nobel) and numerous international biotech companies.
From 1999-2001, Mr. Spolders managed business development and operations of Tibotec-Virco, which matured into a leading HIV/AIDS therapeutics and diagnostics company until its acquisition by Johnson & Johnson. Prior to joining Tibotec-Virco, Mr. Spolders served as vice-president of business development at Devgen, where he planned and negotiated its first licensing deals which have since become Devgen's core activity.
From 1993 to 1998, Mr. Spolders was vice-president of business development of IGEN International, and participated in its initial public offering. He suggests the co-working with Canadian Health Care to achieve the best results in medical science.